William H. Lewis
President, CEO & ChairmanMr. William H. Lewis, J.D. M.B.A. also known as Will, serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2018. Mr. Lewis has executive experience in the pharmaceutical and finance industries both in the U.S. and internationally. Prior to joining Insmed in 2012, Mr. Lewis served as Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, which was acquired by Amryt in 2019. Prior to Aegerion, he spent few years working in investment banking in the U.S. and Europe. Mr. Lewis co-founded Aegerion Pharmaceuticals, Inc. and served as its President from August 2009 to June 2011, Chief Financial Officer since March 2005, Senior Vice President of Finance and Administration from July 2005 to February 2007, Chief Administrative Officer since July 2005, Vice President of Administration from July 2005 to February 2007 and Secretary since July 2005. He has executive experience in the pharmaceutical and finance industries both in the US and internationally. He served as Treasurer at Aegerion Pharmaceuticals, Inc. since July 2005 and its Senior Vice President of Finance & Administration since February 2007. He joined Aegerion Pharmaceuticals in April 2005 and also served as its Principal Accounting Officer and Executive Vice President. He spent many years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. He served at Wells Fargo & Co. (2002 - 2004). He began his career as an Operations Officer with the Central Intelligence Agency. He has been involved in the operation, investing and banking of life sciences companies for many years. He has been involved in the structuring and financing of companies since 1995. Mr. Lewis began his career with JP Morgan, initially in their New York office where he worked on IPO’s, follow-on offerings, carve-outs and private placements. He was transferred to the London office where he continued to work on international financings until early 2000 when he decided to leave to return to the states and pursue work with an investment bank more specifically focused on emerging growth companies. While at Robertson Stephens in Boston, he began to focus on Life Sciences transactions specifically and was responsible for all public and private capital markets transactions in the Life Sciences Group. He served as Head - Private Capital Group of Wells Fargo & Company since May 14, 2003. From August 2004 to March 2005, Mr. Lewis served as Managing Director at a hedge fund, in which he focused on investments in small market capitalization companies. From August 2002 to April 2004, he served as a Managing Director at Wells Fargo Securities and served as its Head of Capital Markets Investment Banking, in which he was responsible for sourcing, overseeing and executing private and public debt and equity transactions. He served as Senior Vice President of Wells Fargo Securities, LLC. From 2000 to 2002, he was a Principal at Robertson Stephens & Company, in which he was responsible for overseeing private and public debt and equity transactions. From 1996 to 2000, Mr. Lewis served as a Vice President of Equity Capital Markets at J.P. Morgan & Co. Inc. in which he focused on private and public equity offerings in the United States and Europe. He began his career with JP Morgan, initially in their New York office where he worked on IPO's, follow-on offerings, carve-outs and private placements. He served as Managing Director of BayStar Capital, LP. Mr. Lewis served as Managing Director and Head of Capital Markets Investment Banking at Wells Fargo & Company since May 14, 2003. He was employed at Robertson Stephens & Co. L.L.C. (RSCO) and served as its Principal and Head of East Coast Capital Markets. Prior to attending graduate school, he worked in the Foreign Service and Operations Officer for the US Government where he received an Officer's commission (1989 - 1992). He has been an Independent Director of Helix Acquisition Corp. since October 19, 2020. He has been a Director of Insmed Incorporated since September 2012 and served as Consultant to Board from June -September 2012. He serves as a Member of the Board of Directors of Oberlin College. He served as a Director of uniQure N.V. since June 11, 2014 until September 14, 2017. He served as a Member of Supervisory Board at uniQure N.V. since June 11, 2014 until June 15, 2016. He is a Member of the Board of trustees of BioNJ and serves as its Chair of the Board of Trustees, the life sciences association for New Jersey and a Member of the Board of trustees of Case Western Reserve University. Mr. Lewis holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University.
Positions
- Company NameInsmed IncorporatedStock CodeINSMPositionPresident, CEO & ChairmanColleagues
- RARoger AdsettChief Operating Officer
- MAMichael Alexander SmithChief Legal Officer & Corporate Secretary
- MFMartina FlammerChief Medical Officer
- BOBrendan O’LearySenior Vice President of Finance
- DRDavid R. BrennanLead Independent Director
- CACarol A. SchaferIndependent Director
- MSMelvin SharokyIndependent Director
- LLLeo LeeIndependent Director
- Company NameNewAmsterdam Pharma Company N.V.Stock CodeNAMSPositionIndependent Chairman of Board of DirectorsRelated SecuritiesColleagues
- MHMichael Harvey DavidsonCEO, President & Executive Director
- WHWilliam H. LewisIndependent Chairman of Board of Directors
- JJJohannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director
- MAMayur Amrat SomaiyaChief Financial Officer
- RWRobert W. GunningPrincipal Accounting Officer, VP & Controller
- MPMatthew PhilippeExecutive VP & Head of Investor Relations
- MCMark C. McKennaIndependent Non-Executive Vice Chairman
- JWJohn W. SmitherIndependent Director
